FDA Approves Onyx Pharma’s Kyprolis – Analyst Blog
Onyx Pharmaceuticals, Inc. ( ONXX ) received a huge boost recently with the US Food and Drug Administration (FDA) approving the company’s multiple myeloma (MM) candidate, Kyprolis (carfilzomib). Kyprolis has been approved for use in treatment-experienced multiple myeloma patients (who have received at least two prior therapies, including Takeda/ Johnson & Johnson’s ( JNJ ) Velcade (bortezomib) and an immunomodulatory agent) and whose disease has progressed on or within 60 days of completion of the last therapy
Read the original:
FDA Approves Onyx Pharma’s Kyprolis – Analyst Blog
BY SHEFALI ANAND MUMBAI—India is about to get its third national stock exchange, just as trading volume here dwindles. MCX Stock Exchange Ltd., known as MCX-SX, has received approval from India’s capital-markets regulator to offer trading in equities and related products, the exchange said. The Securities and Exchange Board of India has given MCX-SX permission to deal in equities, equity futures and options, interest-rate futures and some types of debt instruments, the company said late Tuesday